Peter A. Crooks Institution-verified
Sourced from institutional research profiles (UAMS TRI or ARA).
Drug research
faculty
Research Areas
Biography and Research Information
OverviewAI-generated summary
Peter A. Crooks, Simmons Chair in Cancer Research and Professor and Chairman of the Department of Pharmaceutical Sciences at the University of Arkansas for Medical Sciences, has dedicated over forty years to drug design and discovery, with a significant focus on cancer-related research since the 1980s. His extensive work has resulted in over 560 publications in medicinal chemistry and drug synthesis, alongside more than 100 patents in drug discovery. Crooks is recognized as an international expert in drug design and discovery, possessing substantial expertise in prodrug and codrug design, drug metabolism, and pharmacokinetics, all critical areas for preclinical drug development. He has been a founding member of seven drug discovery companies and has seen several of his discoveries progress to clinical trials. Notably, his anticancer drug Valchlor® has received FDA approval for treating cutaneous T-cell lymphoma, with other drugs also in various phases of clinical development.
His research group's recent publications reflect a diverse engagement with therapeutic development. Studies include investigations into biobanked glioblastoma organoids for precision medicine, novel hybrid compounds for Alzheimer's disease targeting cholinesterase activity, and the mechanisms of parthenolide in inducing ferroptosis in hepatocellular carcinoma cells. Other work explores thiadiazolidinone analogs for neurodegenerative disease models, the therapeutic potential of antihypertensive agents against drug-induced cardiotoxicity, and the antitumor properties of sesquiterpene lactone analogs as NFκB inhibitors. Crooks's scholarly contributions are underscored by a h-index of 57, over 928 total publications, and more than 14,816 citations, marking him as a highly cited researcher.
Metrics
- h-index: 57
- Publications: 928
- Citations: 14,876
Selected Publications
-
Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats (2024)
-
Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan (2023)
-
High flux novel polymeric membrane for renal applications (2023)
-
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2023)
-
Parthenolide induces rapid thiol oxidation that leads to ferroptosis in hepatocellular carcinoma cells (2022)
-
Characterizing the Access of Cholinergic Antagonists to Efferent Synapses in the Inner Ear (2021)
-
Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion (2021)
-
Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease (2021)
-
Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD) (2021)
-
Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity (2021)
-
Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone (2021)
-
A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain (2021)
ARA Academy 2011 ARA Scholar
Grants & Funding
Collaboration Network
Top Collaborators
- Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion
- Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease
- Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan
- Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
Showing 5 of 6 shared publications
- Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease
- Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan
- Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
- A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain
- Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)
- High flux novel polymeric membrane for renal applications
- Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease
- Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan
- Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease
- Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan
- Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion
- Parthenolide induces rapid thiol oxidation that leads to ferroptosis in hepatocellular carcinoma cells
- A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain
- A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain
- A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain
- A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
- Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity
Similar Researchers
Based on overlapping research topics